Physician profile
Jorge E Deltoro
NPI 1730290107
$9,337.54
in general payments reported to CMS, 2019-2025
36 companies · $2,023 in 2025
The $2,023 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $188 · 2021: $493 · 2022: $1,375 · 2023: $1,971 · 2024: $1,962 · 2025: $2,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,847 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,847.15 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,324.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $957.58 | 2022-2025 | Xifaxan |
| Amgen INC. | $917.27 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $880.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $842.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $784.67 | 2019-2025 | Linzess, Ubrelvy, Viberzi |
| Glaxosmithkline, LLC. | $713.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $443.61 | 2019-2025 | Uzedy |
| Merck Sharp & Dohme LLC | $396.27 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $357.53 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $207.72 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Daiichi Sankyo INC. | $162.84 | 2022-2025 | Injectafer |
| Exact Sciences Corporation | $156.26 | 2023-2025 | Cologuard Collection Kit |
| Phadia US INC. | $153.89 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $146.99 | 2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Deltoro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.